• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Guardant Health Announces Project LUNAR, An Ambitious Multi-arm, Multi-site Umbrella Trial to Study Blood Test for Early Cancer Detection

Researchers from Massachusetts General Hospital, Perelman School of Medicine at the University of Pennsylvania, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, UC San Francisco, Samsung Medical Center, the University of Colorado Anschutz Medical Campus, and Other Institutions Will Study the Efficacy of Guardant Health's Liquid Biopsy for Detecting Early-Stage Cancer Across Multiple Indications

Guardant Health. (PRNewsFoto/Guardant Health)

News provided by

Guardant Health

May 26, 2016, 09:00 ET

Share this article

Share this article


SAN FRANCISCO, May 26, 2016 /PRNewswire/ -- Guardant Health announced today the launch of an ambitious initiative, Project LUNAR, which will extend the technology behind the company's market-leading comprehensive liquid biopsy, Guardant360, into early-stage cancer detection.

The company is partnering with leading academic, industrial, and patient advocacy groups to study what would be a novel, first-in-class technology.

"The existence of a minimally invasive, highly sensitive and specific test for early-stage cancer holds the promise of a universal screening test that could change the face of cancer treatment forever," said Guardant Health co-founder and CEO Helmy Eltoukhy, PhD. "In fact, the development of such a test has been Guardant Health's goal from day one. We started with late stage disease, and over the last four years have worked methodically through iterative technology development to arrive at this point. We understand that with any promise of this magnitude comes a responsibility to fully understand its implications, so we continue to bring in experts from advocacy, academia, industry, and public health to support our efforts."

Oncologists and researchers have long sought a minimally invasive, highly sensitive and specific multi-cancer test as a more effective way to catch cancer in its earliest stages, when treatment and prognosis are most promising.

"As a BRCA-carrier with a family history of pancreatic cancer, I know just how important a highly sensitive and specific test can be for a patient," said Dr. Pamela Munster, a UC San Francisco clinical oncologist and co-director of the Center for BRCA Research at UCSF, and one of the Principal Investigators of the LUNAR-Ovarian study. "Particularly for cancers where prophylactic surgeries may not be acceptable, early detection can save lives and can also alleviate anxiety, as well as guide specific screening. Cancer prognosis is nearly always better when the disease is detected early."

LUNAR is an umbrella protocol that Guardant Health is launching with researchers from the Massachusetts General Hospital, Perelman School of Medicine at the University of Pennsylvania, the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, UC San Francisco, Samsung Medical Center, the University of Colorado Anschutz Medical Campus, and other institutions that will study the ability of Guardant Health's technology to detect cancer at early stages in high-risk populations. Guardant Health has already collected samples from multiple trial sites in breast, ovarian, lung, pancreatic, and colorectal cancers, with pilot data expected in the second half of 2016. Guardant expects to enroll thousands of patients in multi-site, multi-arm prospective clinical trials that will demonstrate first the feasibility and then efficacy of early detection of the deadliest cancers, through the integrated use of cell free DNA, imaging, germline risk assessment, and other highly complementary technologies.

"The LUNAR technology, with its great sensitivity necessary for early detection, will establish a new frontier in cancer diagnostics, allowing use of a biological signal instead of standard imaging, and possibly one day replacing invasive procedures," said Dr. Massimo Cristofanilli, Associate Director for Precision Medicine and Translational Research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Professor of Medicine at Northwestern University Feinberg School of Medicine, and one of the Principal Investigators of the LUNAR-Breast study. "The potential applications in breast cancer and other solid tumors can go far beyond early detection to monitor the efficacy and detect resistance to systemic therapies in adjuvant and neo-adjuvant settings."

The company presented an early proof-of-concept study to the American Association for Cancer Research in April that demonstrated its ability to detect cancer in 86% of early-stage colorectal cancer patients with ultra-high specificity. Project LUNAR (an acronym for Liquid biopsy Using NGS to Assay high-Risk patients) will use a newer, more sensitive version of the company's technology than was used in that trial.

"The knowledge gained from processing tens of thousands of Guardant360 patient samples has enabled us to iteratively push the performance limits of our technology to develop an affordable LUNAR assay that can detect a single mutated DNA fragment among hundreds of thousands of genome copies," said Guardant Health President and co-founder AmirAli Talasaz, PhD. "Such a test may potentially have a clinical sensitivity approaching 90% for many cancer types, and could be priced in the hundreds of dollars."

Guardant Health has established its advanced cancer product, Guardant360, as best in class in terms of both sensitivity and specificity, with validated analytical specificity of 99.9999%. High specificity is critical when screening asymptomatic people who are at a high risk for developing cancer.

"False positive findings cause real harm, both in terms of anxiety and the unnecessary invasive procedures they often result in, and have been the downfall of many screening methodologies, especially for lung cancer," said Dr. Anil Vachani, Associate Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania, and one of the Principal Investigators of the LUNAR-Lung study. "Guardant's ctDNA approach may provide the positive predictive value we need to assist in the management of suspicious findings frequently identified using currently employed imaging studies in oncology practice."

There are two reasons why Guardant Health expects its approach to have superb positive predictive value for cancer. First, while many screening signals, like dense tissue on a scan, or an elevated protein biomarker like CEA or PSA, are loosely correlated with a particular cancer, oncogenically-altered DNA is considered to be the major universal pathogenic driver of the disease. It is causal, not correlative. Second, Guardant Health's digital sequencing platform uses advanced molecular biology, novel chemistry, and a bioinformatics digital inference engine to maximize nucleic acid yield and nearly eliminate the errors intrinsic to sequencing.

The potential for extremely high specificity is exciting for the many patient advocacy groups that are learning more about project LUNAR. Eltoukhy said, "The voice of the patient is critical in developing screening methodologies that are not only clinically and scientifically sound, but reflect the real-world needs of patients. That's why Guardant Health has built an advisory committee with the Bonnie J. Addario Lung Cancer Foundation, The BRCA Foundation, Bright Pink, HeritX, and the Lung Cancer Alliance."

Guardant Health will be kicking off Project LUNAR at an event in San Francisco on May 26 that will feature dozens of leading experts and advocates in oncology including a panel conversation between Dr. Eric Topol, endowed Chair of Innovative Medicine at Scripps, and many of the project's collaborators.

About Guardant Health
Guardant Health, headquartered in Redwood City, Calif., is focused on developing breakthrough diagnostics that can transform cancer from a silent killer into a manageable disease. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics and cancer diagnostics. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology.

UC Disclaimer
The information stated above was prepared by Guardant Health and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of Guardant, or any of its products, by The Regents of the University of California, its officers, agents and employees.

Logo - http://photos.prnewswire.com/prnh/20140212/SF64352LOGO

SOURCE Guardant Health

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.